What we know so far

AIDS, Supplement

Volumn 10, Issue 1, 1996, Pages

  Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; Combination therapy; HIV protease inhibitors; Nucleoside analogues

Indexed keywords

DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT CARE; PRIORITY JOURNAL; VIRUS TITRATION;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; NUCLEOTIDES;

EID: 0029826405     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Hammer SM, Katzenstein DA, Hughes MD, Hirsch MS, Merigan TC for the ACTG 175 Virology Substudy Team: Virologic markers and outcome in ACTG 175. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 [symposia S24].
2. Hammer SM, Katzen DA, Hughes MD, et al., for the AIDS Clinical Trial Group Study 175 Study Team: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4+ cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
4. Saravolatz LD, Windslovv DL, Collins G, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4+ cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
5. Cameron B, Heath-Chiozzi M, Kravcik S, et al.: Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir: 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 [abstract LB60].
6. Cameron DW, Heath-Chiozzi M, Kravcik S, et al.: Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.411].
7. Lalezari J, Haubrich R, Burger HU, ef al.: Improved survival and decreased progression of HIV in patients treated with saquinavir plus HIVID. XI International Conference on AIDS. Vancouver, July 1996 [abstract LB.B.6033].
8. Mathez D, De Truchis P, Gorin I, et al.: Ritonavir, AZT, zalcitabine, as a triple combination in AIDS patients. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 [abstract 285].
9. Mathez D, Bagnarelli P, De Truchis P, et al.: A triple combination of ritonavir+AZT+ zalcitabine as a first line treatment of patients with AIDS: update. XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.175].
10. Baruch A, Mastrodonato-Delora P, Schnipper E, Salgo M: Efficacy and safety of triple combination therapy with invirase, epivir and retrovir, in HIV-infected patients. XI Conference on AIDS. Vancouver, July 1996 [abstract Mo.B.172].
11. Workman C, Downie J, Sutherland D, et al.: Rapid viral load decrease in primary infection associated with aggressive therapy. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 [abstract].
12. Schooley RT, Cooper D, Moore MD, McKinnis R, Rooney JF: Initial combination therapy with zidovudine + didanosine or zidovudine + zalcitabine vs zidovudine. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 [abstract 202].
13. Loveday C on behalf of the Delta Virology Group: HIV 1 genotypic and phenotypic resistance in Delta patients. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 1996 [LB5c].
14. Jacobsen H, Haenggi M, Ott M, et al.: Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Antiviral Res 1996, 29:95-97.
15. 3. XI International Conference on AIDS. Vancouver, July 96 [abstract Mo.B.294].